Telaprevir to boceprevir switch highlights lack of cross-reactivity.

ABSTRACT: Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.

SUBMITTER: Carlson A 

PROVIDER: S-EPMC3732052 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature